Ausgabe 2/2020
Inhalt (16 Artikel)
Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy
Richard C. Becker, A. Phillip Owens III, Sakthivel Sadayappan
Rationale and design of “Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)” study
Ying X. Gue, Rahim Kanji, David M. Wellsted, Manivannan Srinivasan, Solange Wyatt, Diana A. Gorog
Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels
Alex M. Ebied, Tammy Li, Samantha F. Axelrod, Douglas J. Tam, Yiqing Chen
Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism
Ming Sheng Lim, Dee Nandurkar, Ian Jong, Anita Cummins, Huyen Tran, Sanjeev Chunilal
Induction of tissue factor expression by anti-β2-glycoprotein I is mediated by tumor necrosis factor α
Anne Hollerbach, Nadine Müller-Calleja, Antje Canisius, Carolin Orning, Karl J. Lackner
Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction
Ugochukwu Shola Owolabi, Alok Ravindra Amraotkar, Amanda R. Coulter, Narayana Sarma V. Singam, Bahjat N. Aladili, Ayesha Singh, Patrick James Trainor, Riten Mitra, Andrew Paul DeFilippis
Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status
Bohyun Kim, Seongsoo Jang, Yu-Jin Lee, Nuree Park, Young-Uk Cho, Chan-Jeoung Park
Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients
Jacob T. Beyer, Stuart E. Lind, Sheila Fisher, Toby C. Trujillo, Michael F. Wempe, Tyree H. Kiser
Direct oral anticoagulants: a review on the current role and scope of reversal agents
Rahul Chaudhary, Tushar Sharma, Jalaj Garg, Ajaypaul Sukhi, Kevin Bliden, Udaya Tantry, Mohit Turagam, Dhanunjaya Lakkireddy, Paul Gurbel
Low persistence to rivaroxaban or warfarin among patients with new venous thromboembolism at a safety net academic medical center
Sweta Meet Patel, Tina Wang, Desire Lashalle Outler, Jennifer Elliott, Michael Knauss, Samuel K. Peasah, Mikhail Akbashev
Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care
Markus Gulilat, Denise Keller, Bradley Linton, A. Demetri Pananos, Daniel Lizotte, George K. Dresser, Jeffrey Alfonsi, Rommel G. Tirona, Richard B. Kim, Ute I. Schwarz
Factors associated with women’s adherence to postpartum thromboprophylaxis
Amihai Rottenstreich, Adi Karlin, Yosef Kalish, Gabriel Levin, Misgav Rottenstreich
Congenital fibrinogen disorders with repeated thrombosis
Xiuli Zhang, Chuang Zhang, Baoheng Wang, Ningheng Chen, Gaihe Sun, Xueli Guo
Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project
Maria R. Bernstein, Libiny John, Susan Sciortino, Elise Arambages, Danielle Auletta, Alex C. Spyropoulos
Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more
Bernhard Wernly, Deepak L. Bhatt, Amin Polzin, Christian Jung
A case report of severe bleeding due to lupus anticoagulant hypoprothrombinemia syndrome
Elsa Meireles, Filipe Machado, Luís Teles, Anna Chumakova, Joana Sequeira, Ana Spínola